MDT

83.06

+0.24%↑

VEEV

213.48

-0.09%↓

A

103.34

+2.82%↑

HQY

80.25

+4.9%↑

PDCO

30.85

-0.29%↓

MDT

83.06

+0.24%↑

VEEV

213.48

-0.09%↓

A

103.34

+2.82%↑

HQY

80.25

+4.9%↑

PDCO

30.85

-0.29%↓

MDT

83.06

+0.24%↑

VEEV

213.48

-0.09%↓

A

103.34

+2.82%↑

HQY

80.25

+4.9%↑

PDCO

30.85

-0.29%↓

MDT

83.06

+0.24%↑

VEEV

213.48

-0.09%↓

A

103.34

+2.82%↑

HQY

80.25

+4.9%↑

PDCO

30.85

-0.29%↓

MDT

83.06

+0.24%↑

VEEV

213.48

-0.09%↓

A

103.34

+2.82%↑

HQY

80.25

+4.9%↑

PDCO

30.85

-0.29%↓

Search

Bristol-Myers Squibb Co.

Slēgts

SektorsVeselības aprūpe

55.17 0.42

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

52.76

Max

55.27

Galvenie mērījumi

By Trading Economics

Ienākumi

-1.1B

76M

Pārdošana

442M

12B

P/E

Sektora vidējais

14.05

63.778

EPS

1.67

Dividenžu ienesīgums

4.07

Peļņas marža

0.616

Darbinieki

34,100

EBITDA

-1.9B

2.6B

Rekomendācijas

By TipRanks

Rekomendācijas

Neitrāls

Prognoze 12 mēnešiem

+10.18% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

4.07%

2.39%

Nākamie ieņēmumi

2025. g. 24. apr.

Nākamais dividenžu datums

2025. g. 1. maijs

Nākamais Ex dividenžu datums

2025. g. 4. jūl.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

311M

121B

Iepriekšējā atvēršanas cena

54.75

Iepriekšējā slēgšanas cena

55.17

Ziņu noskaņojums

By Acuity

30%

70%

85 / 386 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

Bristol-Myers Squibb Co. Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 11. marts 10:13 UTC

Galvenie tirgus virzītāji
Iegādes, apvienošanās, pārņemšana

2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers

2025. g. 11. marts 10:13 UTC

Galvenie tirgus virzītāji
Iegādes, apvienošanās, pārņemšana

2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers

2025. g. 6. febr. 12:13 UTC

Peļņas

Bristol Myers Squibb's 4Q Beats Forecasts; Generics Dent 2025 Outlook

2025. g. 14. marts 09:30 UTC

Top Ziņas

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

2025. g. 11. marts 02:26 UTC

Iegādes, apvienošanās, pārņemšana

Abecma Is an Immunotherapy Indicated for Treatment of Relapsed or Refractory Multiple Myeloma >TSVT

2025. g. 11. marts 02:26 UTC

Iegādes, apvienošanās, pārņemšana

Stockholders Owning About 5.3% of 2seventy Bio Shares Have Agreed to Tender All Their Shares >TSVT

2025. g. 11. marts 02:26 UTC

Iegādes, apvienošanās, pārņemšana

2seventy Bio CEO: Rationale for Deal Clear, in Line With Focus on Unlocking Value of Abecma >TSVT

2025. g. 11. marts 02:23 UTC

Iegādes, apvienošanās, pārņemšana

2seventy Bio Stock Will No Longer Trade on Nasdaq After Closing of Deal, Expected in 2Q >TSVT

2025. g. 11. marts 02:22 UTC

Iegādes, apvienošanās, pārņemšana

2seventy Bio's Board Unanimously Recommends Stockholders Tender Shares in Offer >TSVT

2025. g. 11. marts 02:21 UTC

Iegādes, apvienošanās, pārņemšana

Bristol Myers Deal Represents 88% Premium to 2seventy Closing Price of $2.66 on March 7 >TSVT

2025. g. 11. marts 02:21 UTC

Iegādes, apvienošanās, pārņemšana

Bristol Myers to Acquire 2seventy Bio Shares at $5.00 Each in All-Cash Deal for Equity Value of About $286M >TSVT

2025. g. 11. marts 02:19 UTC

Iegādes, apvienošanās, pārņemšana

2seventy Bio Enters Into Definitive Agreement to Be Acquired by Bristol Myers Squibb

2025. g. 28. febr. 12:00 UTC

Top Ziņas

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

2025. g. 6. febr. 15:35 UTC

Peļņas

Bristol Myers Wallops Fourth-Quarter Views, But Shares Slide On 2025 Outlook -- IBD

2025. g. 6. febr. 13:56 UTC

Peļņas

Bristol Myers Wallops Fourth-Quarter Earnings Views. But Shares Plummet 5%. -- IBD

2025. g. 6. febr. 13:25 UTC

Top Ziņas
Peļņas

Bristol Myers Earnings Are a 'Tale of 2 Trends' as Guidance Falls Short. The Stock Is Falling -- Barrons.com

2025. g. 6. febr. 12:00 UTC

Peļņas

Bristol Myers Earnings Are 'a Tale of 2 Trends' as Guidance Falls Short -- Barrons.com

2025. g. 6. febr. 11:59 UTC

Peļņas

Bristol-Myers Squibb 4Q Gross Margin 61.0% >BMY

2025. g. 6. febr. 11:59 UTC

Peļņas

Bristol-Myers Squibb 4Q Rev $12.3B >BMY

2025. g. 6. febr. 11:59 UTC

Peļņas

Bristol-Myers Squibb 4Q Net $72M >BMY

2025. g. 6. febr. 11:59 UTC

Peļņas

Bristol-Myers Squibb 4Q EPS 4c >BMY

2025. g. 6. febr. 11:59 UTC

Peļņas

Bristol-Myers Squibb 4Q Adj EPS $1.67 >BMY

2025. g. 6. febr. 11:59 UTC

Peļņas

Bristol Myers Squibb: Expanding Existing Strategic Productivity Initiative to Include About $2B in Additional Annualized Cost Savings by the End of 2027 >BMY

2025. g. 6. febr. 11:59 UTC

Peļņas

Bristol Myers Squibb 4Q International Revenue Rose 5% to $3.7B >BMY

2025. g. 6. febr. 11:59 UTC

Peļņas

Bristol Myers Squibb 4Q U.S. Revenue Rose 9% to $8.6B >BMY

2025. g. 6. febr. 11:59 UTC

Peļņas

Bristol Myers Squibb 4Q Legacy Portfolio Revenue $5.98B, Down 4% >BMY

2025. g. 6. febr. 11:59 UTC

Peļņas

Bristol Myers Squibb: 4Q Growth Portfolio Revenue Primarily Due to Higher Demand for Reblozyl, Breyanzi, Camzyos, Yervoy and Opdualag >BMY

2025. g. 6. febr. 11:59 UTC

Peļņas

Bristol Myers Squibb 4Q Rev $12.34B >BMY

2025. g. 6. febr. 11:59 UTC

Peļņas

Bristol Myers Squibb: 4Q Legacy Portfolio Revenue Lower Vs Yr-Ago Primarily Due to Impact of Generics on Sprycel, Revlimid, Abraxane and Pomalyst, Partially Offset by Higher Demand for Eliquis >BMY

2025. g. 6. febr. 11:59 UTC

Peļņas

Bristol Myers Squibb: 2025 Rev Outlook Reflects Near-Term Impact of Generics Across Revlimid, Pomalyst, Sprycel and Abraxane >BMY

Salīdzinājums

Cenas izmaiņa

Bristol-Myers Squibb Co. Prognoze

Cenas mērķis

By TipRanks

10.18% augšup

Prognoze 12 mēnešiem

Vidējais 60.93 USD  10.18%

Augstākais 70 USD

Zemākais 37 USD

Pamatojoties uz 16 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Bristol-Myers Squibb Co. — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

16 ratings

5

Pirkt

10

Turēt

1

Pārdot

Tehniskais rādītājs

By Trading Central

N/A / 59.18Atbalsts un pretestība

Īstermiņā

Bearish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Weak Bearish Evidence

Noskaņojums

By Acuity

85 / 386 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.